202 related articles for article (PubMed ID: 30763392)
61. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis.
Chen X; Yuan Y; Gu Z; Shen K
Breast Cancer Res Treat; 2012 Aug; 134(3):957-67. PubMed ID: 22370627
[TBL] [Abstract][Full Text] [Related]
62. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability.
Kleer CG; van Golen KL; Zhang Y; Wu ZF; Rubin MA; Merajver SD
Am J Pathol; 2002 Feb; 160(2):579-84. PubMed ID: 11839578
[TBL] [Abstract][Full Text] [Related]
63. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
64. Dielectric and FT-Raman spectroscopic approach to molecular identification of breast tumor tissues.
Abd El-Hakam R; Khalil S; Mahani R
Spectrochim Acta A Mol Biomol Spectrosc; 2015; 151():208-12. PubMed ID: 26142175
[TBL] [Abstract][Full Text] [Related]
65. Raman spectroscopy and imaging: applications in human breast cancer diagnosis.
Brozek-Pluska B; Musial J; Kordek R; Bailo E; Dieing T; Abramczyk H
Analyst; 2012 Aug; 137(16):3773-80. PubMed ID: 22754917
[TBL] [Abstract][Full Text] [Related]
66. Raman spectroscopy can differentiate malignant tumors from normal breast tissue and detect early neoplastic changes in a mouse model.
Kast RE; Serhatkulu GK; Cao A; Pandya AK; Dai H; Thakur JS; Naik VM; Naik R; Klein MD; Auner GW; Rabah R
Biopolymers; 2008 Mar; 89(3):235-41. PubMed ID: 18041066
[TBL] [Abstract][Full Text] [Related]
67. Clinicopathologic analysis of breast lesions associated with multiple papillomas.
Ali-Fehmi R; Carolin K; Wallis T; Visscher DW
Hum Pathol; 2003 Mar; 34(3):234-9. PubMed ID: 12673557
[TBL] [Abstract][Full Text] [Related]
68. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
69. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
70. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS; Kim SW
Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
[TBL] [Abstract][Full Text] [Related]
71. Diagnosing molecular subtypes of breast cancer by means of Raman spectroscopy.
Melitto AS; Arias VEA; Shida JY; Gebrim LH; Silveira L
Lasers Surg Med; 2022 Oct; 54(8):1143-1156. PubMed ID: 35789102
[TBL] [Abstract][Full Text] [Related]
72. Low protein expression of MET in ER-positive and HER2-positive breast cancer.
Zagouri F; Brandstetter A; Moussiolis D; Chrysikos D; Dimitrakakis C; Tsigginou A; Marinopoulos S; Zografos GC; Sergentanis TN; Dimopoulos MA; Filipits M
Anticancer Res; 2014 Mar; 34(3):1227-31. PubMed ID: 24596364
[TBL] [Abstract][Full Text] [Related]
73. Raman spectroscopy of normal and diseased human breast tissues.
Frank CJ; McCreery RL; Redd DC
Anal Chem; 1995 Mar; 67(5):777-83. PubMed ID: 7762814
[TBL] [Abstract][Full Text] [Related]
74. ER, PR, and Her2 immunocytochemistry on cell-transferred cytologic smears of primary and metastatic breast carcinomas: a comparison study with formalin-fixed cell blocks and surgical biopsies.
Ferguson J; Chamberlain P; Cramer HM; Wu HH
Diagn Cytopathol; 2013 Jul; 41(7):575-81. PubMed ID: 22807465
[TBL] [Abstract][Full Text] [Related]
75. Vimentin expression in benign and malignant breast epithelium.
Heatley M; Whiteside C; Maxwell P; Toner P
J Clin Pathol; 1993 May; 46(5):441-5. PubMed ID: 7686566
[TBL] [Abstract][Full Text] [Related]
76. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
77. Development and comparative assessment of Raman spectroscopic classification algorithms for lesion discrimination in stereotactic breast biopsies with microcalcifications.
Dingari NC; Barman I; Saha A; McGee S; Galindo LH; Liu W; Plecha D; Klein N; Dasari RR; Fitzmaurice M
J Biophotonics; 2013 Apr; 6(4):371-81. PubMed ID: 22815240
[TBL] [Abstract][Full Text] [Related]
78. [Value of vacuum assisted biopsies under sonography guidance: results from a multicentric study of 650 lesions].
Sebag P; Tourasse C; Rouyer N; Lebas P; Dénier JF; Michenet P
J Radiol; 2006 Jan; 87(1):29-34. PubMed ID: 16415777
[TBL] [Abstract][Full Text] [Related]
79. Breast cancer detection based on serum sample surface enhanced Raman spectroscopy.
Vargas-Obieta E; Martínez-Espinosa JC; Martínez-Zerega BE; Jave-Suárez LF; Aguilar-Lemarroy A; González-Solís JL
Lasers Med Sci; 2016 Sep; 31(7):1317-24. PubMed ID: 27289243
[TBL] [Abstract][Full Text] [Related]
80. Raman spectroscopy: current applications in breast cancer diagnosis, challenges and future prospects.
Hanna K; Krzoska E; Shaaban AM; Muirhead D; Abu-Eid R; Speirs V
Br J Cancer; 2022 May; 126(8):1125-1139. PubMed ID: 34893761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
